Video

Access to High Cost Drugs Remains a Challenge in Specialty

Author(s):

Lauren Santye, Assistant Editor

Paul LeVine, vice president of Analytic Services at Trial Card, discusses potential ways to overcome the hurdle of limited access to high cost specialty drugs.

Paul LeVine, vice president of Analytic Services at Trial Card, discusses potential ways to overcome the hurdle of limited access to high cost specialty drugs.

Related Videos
Related Content
Bladder and prostate stamped on wooden cubes, prostate cancer, bladder cancer, male healthcare concept, regular prostate checkup.
December 23rd 2024

FDA Approves Vibegron for Men With Overactive Bladder Symptoms Receiving Therapy for Benign Prostatic Hyperplasia

Luke Halpern, Assistant Editor
Pharmacy Focus: Oncology Edition - Discussing Increasing Rates of Lung Cancer in Young Adults and Emerging Precision Treatments
November 25th 2024

Pharmacy Focus: Oncology Edition - Discussing Increasing Rates of Lung Cancer in Young Adults and Emerging Precision Treatments

ASHP Midyear: Vaccination Among Older Adults Prevents Severe RSV Infections
December 23rd 2024

ASHP Midyear: Vaccination Among Older Adults Prevents Severe RSV Infections

Pharmacy Focus: Oncology Edition- Exploring Pelareorep: A Novel Immunotherapy for Advanced Breast Cancer
October 28th 2024

Pharmacy Focus: Oncology Edition- Exploring Pelareorep: A Novel Immunotherapy for Advanced Breast Cancer

FDA website homepage -- Image credit: Postmodern Studio | stock.adobe.com
December 21st 2024

FDA Approves Alyftrek, Once-Daily CFTR Modulator for Cystic Fibrosis

Gillian McGovern, Assistant Editor
FDA Approves Expanded Use for Trikafta in Cystic Fibrosis
December 20th 2024

FDA Approves Expanded Use for Trikafta in Cystic Fibrosis

Aislinn Antrim, Assistant Managing Editor